Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.25 per share a year ago.

Medtronic (MDT) Surpasses Q2 Earnings and Revenue Estimates

Medtronic beat quarterly expectations Tuesday, but Medtronic stock dipped near a sell zone in premarket trading. The post Medtronic Beats And Raises, But Shares Flirt With A Sell Zone appeared first on Investor's Business Daily.

Medtronic Beats And Raises, But Shares Flirt With A Sell Zone

Medtronic lifted the lower end of its annual profit forecast for a second time, banking on sustained demand for its medical devices in the U.S. and sending its shares up nearly 2% in premarket trading on Tuesday.

Medtronic lifts annual profit view on strong demand for medical devices

Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises:  TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland , Nov. 19, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024. Key Highlights Revenue of $8.4 billion increased 5.3% as reported and 5.0% organic GAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.26 Company raises FY25 organic revenue growth and EPS guidance Financial Results Medtronic reported Q2 worldwide revenue of $8.403 billion, an increase of 5.3% as reported and 5.0% on an organic basis.

Medtronic reports second quarter fiscal 2025 financial results

BHP Billiton

Canadian Imperial Bank of Commerce

Eastman Chemical

Haleon PLC

MDU Resources Group

Philip Morris

Starbucks

Visa

Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, such as MDU Resources and Haleon.

Dividend Income: Lanny's October 2024 Summary

The latest trading day saw Medtronic (MDT) settling at $87.53, representing a +1.78% change from its previous close.

Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know

Besides Wall Street's top -and-bottom-line estimates for Medtronic (MDT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024.

Insights Into Medtronic (MDT) Q2: Wall Street Projections for Key Metrics

A Beverly Hills surgeon is suing Medtronic claiming patent infringement of her hernia repair mesh product. It's the latest in a series of patent challenges against Medtronic.

Beverly Hills surgeon sues Medtronic for patent infringement

Micron Technology

Oracle

Oracle, Micron Technology, Medtronic and The Cato are included in this Analyst Blog.

The Zacks Analyst Blog Oracle, Micron Technology, Medtronic and The Cato

The latest trading day saw Medtronic (MDT) settling at $87.72, representing a -0.45% change from its previous close.

Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.

Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?

Johnson & Johnson

Royalty Pharma

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

GALWAY, Ireland , Nov. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its second quarter of fiscal year 2025

Merck

These are the kinds of stocks that can allow investors to sleep easy at night.

2 Dividend Stocks to Buy for a Lifetime of Passive Income

Medtronic (MDT) reachead $90.07 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.

Medtronic (MDT) Outperforms Broader Market: What You Need to Know

The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure  GALWAY, Ireland , Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter

Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock

Abbott Labs

Archer-Daniels-Midland Company

Albemarle

Becton, Dickinson and Co.

Franklin Resources

C.H. Robinson Worldwide

Genuine Parts

Hormel Foods

McCormick

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

PepsiCo

PPG Industries

J. M. Smucker

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Target

T. Rowe Price Group

The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 39 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher dividend yield.

My Best Dividend Aristocrats For November 2024

In the most recent trading session, Medtronic (MDT) closed at $90.60, indicating a +0.01% shift from the previous trading day.

Medtronic (MDT) Ascends But Remains Behind Market: Some Facts to Note

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial GALWAY, Ireland and WASHINGTON , Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity™ Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).

SPYRAL HTN-ON MED study shows significant, consistent, long-term blood pressure lowering effect at two years

First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety and efficacy as well as improved workflow and short learning curve Now with two pulsed field ablation (PFA) offerings and a portfolio of electrophysiology solutions, Medtronic is shaping the future of arrythmia treatment today GALWAY, Ireland , Oct. 24, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one, high-density (HD) mapping and pulsed field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter. With this approval, Medtronic is now the first and only company with two PFA technologies available for patients with Afib.

A new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

MDT vs. ABT: Which Stock Is the Better Value Option?

In the latest trading session, Medtronic (MDT) closed at $89.36, marking a +0.57% move from the previous day.

Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Medtronic remains an attractive investment due to its diversified revenue streams, robust product pipeline and improving margins. MDT's growth is driven by strong performance in Neuroscience, Cardiovascular, and Diabetes care, with significant international revenue growth and a promising product pipeline. Trading below its historical valuation, MDT offers a compelling opportunity for conservative investors seeking quality at a reasonably low price.

Medtronic: Undervalued Dividend Aristocrat With High Margins

The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

News for Medtronic Stock (MDT)